Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 25,93 € (+109,96 %). La médiane est de 25,93 € (+109,96 %).
| Acheter |
13 |
| Conserver |
0 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
MediWound: VALUE study for EscharEx as decisive near-term catalyst
MediWound presented its bromelain platform at the H.C. Wainwright conference, highlighting NexoBrid revenue potential and the upcoming VALUE phase III study for EscharEx as key drivers. The VALUE study (216 patients) includes an interim analysis at ~65% recruitment; various sample-size adjustments are possible, and topline data are expected about three months after the interim analysis. The company is expanding production capacity, expects European approval in mid‑2027, and points to commercial progress with NexoBrid as well as a BARDA-linked partnership with Vericel. » Plus sur de.investing.com
MediWound calls extraordinary general meeting for Feb. 19
MediWound has called an extraordinary general meeting for Feb. 19, 2026, and on Jan. 15, 2026 filed the related notice and a proxy statement with the SEC. Registered shareholders will receive voting materials and a proxy card. The filings give meeting details but do not disclose specific agenda items; the documents refer to existing registration statements on Forms S-8 and F-3. » Plus sur de.investing.com
MediWound: study shows NexoBrid removes over 90% of traumatic tattoos
A prospective study at Sheba Medical Center found that MediWound’s enzymatic preparation NexoBrid reduced the pigmented wound surface by an average of 92.5% in 15 patients (96% for abrasion injuries, 84% for blast injuries). The treatment was administered at the bedside under sedation within 24 hours and showed no treatment-related adverse events in early follow-up. MediWound recently raised around $30 million via a direct offering, received approval in Australia and is planning production and capacity expansions; one analyst raised the price target. » Plus sur de.investing.com
MediWound raises $30 million through registered direct placement
MediWound sold 1,734,105 ordinary shares at $17.30 per share in a registered direct placement, raising about $30 million. The transaction was led by a U.S. investment fund and other healthcare-focused investors; H.C. Wainwright & Co. served as sole placement agent. Net proceeds are intended to fund precommercial activities for EscharEx, expand manufacturing capacity and general corporate purposes. The company also reported TGA approval of NexoBrid in Australia and new study data on the importance of wound bed preparation. » Plus sur de.investing.com
MediWound presents growth plan and cites supply bottlenecks for NexoBrid
MediWound presented its growth strategy at the H.C. Wainwright conference, focusing on the phase-3 study of EscharEx and expansion of production capacity. The company reported supply chain problems with NexoBrid and plans a new manufacturing site in the US as well as an additional facility in Europe to address the shortages. Partnerships with BARDA and the DOD, cash of $33 million and a potential $30 million from warrants support the commercialization plans; a BARDA tender is expected in Q4 2025. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 3,15 M | 31,81 % |
| Bénéfice brut | 897,86 k | 17,60 % |
| Bénéfice net | -5,29 M | 133,89 % |
| EBITDA | -7,2 M | 287,68 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 159,14 M € |
Nombre d'actions | 12,91 M |
Plus haut/bas sur 52 semaines | 20,10 € - 10,73 € |
| Dividendes | Non |
Bêta | 0,14 |
Ratio P/E | -7,45 |
Ratio PEG | 0,94 |
Ratio P/B | 5,53 |
Ratio P/S | 17,48 |
Profil de l'entreprise
MediWound Ltd., une société biopharmaceutique, développe, fabrique et commercialise des solutions novatrices et biothérapeutiques pour la réparation et la régénération des tissus. Elle commercialise NexoBrid, un produit biopharmaceutique destiné à l'élimination de l'escarre, un tissu mort ou endommagé, chez les adultes présentant des brûlures thermiques profondes d'épaisseur partielle et totale, dans les centres de traitement des grands brûlés et les unités de traitement des brûlures des hôpitaux. La société développe également EscharEx, qui a achevé les essais cliniques de phase II pour le débridement des plaies chroniques et d'autres plaies difficiles à cicatriser, ainsi que MW005, actuellement en phase I/II pour le traitement du carcinome basocellulaire à faible risque. MediWound Ltd. a été fondée en 2000 et son siège social est situé à Yavne, en Israël.
| Nom | MediWound |
| PDG | Ofer Gonen |
| Siège social | Yavne,
hm Israël |
| Site web | |
| Secteur | Consommation de base |
| Industrie | Produits de soins personnels |
| Introduction en bourse | 20/03/2014 |
| Employés | 121 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | MDWD |
Frankfurt | M8W.F |